Efficacy and safety of fosmidomycin–piperaquine as nonartemisinin-based combination therapy for uncomplicated falciparum malaria: A single-arm, age de-escalation …
G Mombo-Ngoma, J Remppis, M Sievers… - Clinical Infectious …, 2018 - academic.oup.com
Background Fosmidomycin–piperaquine is being developed as nonartemisinin-based
combination therapy to meet the challenge of emerging artemisinin resistance. Methods The …
combination therapy to meet the challenge of emerging artemisinin resistance. Methods The …
Drug repositioning for novel antitrichomonas from known antiprotozoan drugs using hierarchical screening
A Meneses-Marcel, Y Marrero-Ponce… - Future Medicinal …, 2018 - Future Science
Aim: Metronidazole is the most widely used drug in trichomoniasis therapy. However, the
emergence of metronidazole-resistant Trichomonas vaginalis isolates calls for the search for …
emergence of metronidazole-resistant Trichomonas vaginalis isolates calls for the search for …
[HTML][HTML] Molecular Modeling, Structural Analysis and Evaluation of 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase (DXR) as a Putative Drug Target For …
I Icen-Taskin, O Munzuroglu - Brazilian Archives of Biology and …, 2018 - SciELO Brasil
The apicomplexan parasite Theileria parva, the causative agent of ECF, is an important
pathogen affecting both domestic and wild animals, causing major economic losses in the …
pathogen affecting both domestic and wild animals, causing major economic losses in the …